Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia

被引：66

作者：

Labrie, F. ^{[1
]}

Archer, D. F. ^{[2
]}

Bouchard, C. ^{[3
]}

Fortier, M. ^{[3
]}

Cusan, L. ^{[1
]}

Gomez, J. -L. ^{[1
]}

Girard, G. ^{[4
]}

Baron, M. ^{[5
]}

Ayotte, N. ^{[6
]}

Moreau, M. ^{[7
]}

Dube, R. ^{[8
]}

Cote, I. ^{[1
]}

Labrie, C. ^{[1
]}

Lavoie, L. ^{[1
]}

Berger, L. ^{[1
]}

Gilbert, L. ^{[9
]}

Martel, C. ^{[1
]}

Balser, J. ^{[10
]}

机构：

[1] EndoCeutics Inc, Quebec City, PQ, Canada

[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA

[3] Clin Rech Sante Femmes, Quebec City, PQ, Canada

[4] Diex Rech Inc, Sherbrooke, PQ, Canada

[5] Rapid Med Res Inc, Cleveland, OH USA

[6] Clin Gynecol, Shawinigan, PQ, Canada

[7] Montreal Clin Study Ctr, Montreal, PQ, Canada

[8] Univ Quebec, Ctr Hosp, Quebec City, PQ, Canada

[9] McGill Univ, Montreal, PQ, Canada

[10] Veristat Inc, Boston, MA USA

来源：

CLIMACTERIC | 2011年 / 14卷 / 02期

关键词：

HORMONE-REPLACEMENT THERAPY; HEALTHY POSTMENOPAUSAL WOMEN; ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; VAGINAL ATROPHY; SERUM DHEA; CANCER; BREAST; RISK; ESTRADIOL;

D O I：

10.3109/13697137.2010.535226

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Methods aEuro integral This prospective, randomized, double-blind and placebo-controlled phase III clinical trial studied the effect of prasterone (DHEA) applied locally in the vagina on the severity of dyspareunia in 114 postmenopausal women who had identified dyspareunia as their most bothersome symptom of vaginal atrophy, while meeting the criteria for superficial cells < a parts per thousand currency sign aEuroS5%% and pH aEuroS > aEuroS5.0 at both screening and day 1. Results aEuro integral At the standard duration of 12 weeks of treatment, increasing doses of 0.25%%, 0.5%% and 1.0%% DHEA decreased the percentage of parabasal cells by 48.6 aEuroS +/-+/- aEuroS6.78%%, 42.4 aEuroS +/-+/- aEuroS7.36%% and 54.9 aEuroS +/-+/- aEuroS6.60%% (p aEuroS < aEuroS0.0001 vs. placebo for all) with no change with placebo (p aEuroS== aEuroS0.769). The effects on superficial cells and pH were also highly significant compared to placebo at all DHEA doses. The severity score of pain at sexual activity decreased by 0.5, 1.4, 1.6 and 1.4 units in the placebo and 0.25%%, 0.5%% and 1.0%% DHEA groups, respectively, with the p value of differences from placebo ranging from 0.0017 to < aEuroS0.0001. Conclusions aEuro integral Intravaginal DHEA, through local estrogen and androgen formation, causes a rapid and highly efficient effect on pain at sexual activity without systemic exposure of the other tissues, thus avoiding the recently reported systemic effects of estrogens.

引用

页码：282 / 288

页数：7

共 50 条

[1]

[Anonymous], 1993, ANAL QUANT CYTOL, V15, P358

[2]

Archer DF, 2007, J REPROD MED, V52, P159

[3] A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause [J].